← Back to Portfolio

SFJ Pharmaceuticals - SFJ-NSCLC

SFJ-NSCLC and Pfizer are conducting a late-stage trial of Pfizer's potential non-small cell lung cancer (NSCLC) treatment dacomitinib. Usually drugs are launched in Japan and Asia several years after they have been launched in the US and other developed countries, limiting the therapeutic options available to physicians and patients. SFJ-NSCLC intends to reduce this delay.

Location Pleasanton, California
CEO Robert DeBenedetto
Partner Ken Haas
Website www.sfj-pharma.com